PremiumThe FlyCiti ups ArriVent price target to $40, adding ‘upside 90-day short-term view’ ArriVent Biopharma announces interim firmonertinib data from Phase 1b study ArriVent BioPharma Elects Directors at Annual Meeting PremiumThe FlyArriVent Biopharma price target raised to $40 from $39 at H.C. Wainwright ArriVent BioPharma Advances Cancer Pipeline in Q1 2025 ArriVent BioPharma: Promising Clinical Developments and Strategic Advancements Justify Buy Rating PremiumThe Flynew option listings on April 9th ArriVent Biopharma management to meet with Oppenheimer ArriVent Biopharma initiated with a Buy at B. Riley 
